Mood Stabilizer Pharmacogenomics Biobank (MoStGen)

Overview

About this study

The purpose of this study is to create a larger database and bio-repository to examine pharmacogenomics in patients with BD type I and type II treated with mood stabilizing anticonvulsants, atypical antipsychotics and antidepressant medications. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age 18-80 years, male, female, any race/ethnicity.
  • Diagnosis of bipolar I disorder or bipolar II disorder, or bipolar (BP) schizoaffective defined by DSM-IV or DSM-V criteria, SCID- confirmed. If patient has already completed a DSM-IV or DSM-V SCID within one year of enrollment, they will not be required to repeat the SCID assessment.
  • Ability for a referring clinician or research clinician to complete a retrospective clinical assessment of response to lithium, mood stabilizing anticonvulsants(carbamazepine, oxcarbamazepine, divalproex sodium, lamotrigine, zonisamide) typical and atypical antipsychotics, stimulants and related compounds (modafinil / armodafinil) and, unimodal antidepressants utilizing the Alda scale.

Exclusion Criteria: 

  • Inability to understand English.
  • Inability or unwillingness to provide informed consent or scoring less than 80% on the comprehension assessment (CA) form.
  • Unwilling to consent to providing bio-specimens to be stored in the biobank for an indefinite amount of time and to be used in future research studies of as yet unknown design.
  • Actively psychotic (i.e., impaired judgment, false fixed beliefs which are delusions or hallucinations) or active suicidal behavior (including active suicidal ideation or planning).
  • A score of 20 or higher on the YMRS, OR a score of 6 or higher on question #8 of the YMRS.
  • Immunocompromised patients who have received a blood transfusion within the past 6 weeks.
  • Involuntary patients.

Eligibility last updated 9/25/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Austin, Minn.

Mayo Clinic principal investigator

Ashok Seshadri, M.D.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Laura Harper CCRP

(507) 255-9352

Harper.Laura1@mayo.edu

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Osama Abulseoud, M.D.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Yaqqira Womack M.S.

(480) 342-6677

Womack.Yaqqira@mayo.edu

Mankato, Minn.

Mayo Clinic principal investigator

Satyajit Mohite, M.D., M.P.H.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Laura Harper CCRP

(507) 255-9352

Harper.Laura1@mayo.edu

Rochester, Minn.

Mayo Clinic principal investigator

Mark Frye, M.D.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Mark Frye M.D.

(507) 255-9412

MFrye@mayo.edu

More information

Publications

Publications are currently not available